Amgen recently presented 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society, which took place in Boston.
Included in these presentations was analysis from the company’s Phase 2 study highlighting the efficacy of erenumab in patients who suffered 15 or more headache days a month and who had a recent history of acute migraine medication overuse.
Amgen also delivered the results from two Phase 3 studies of the drug that examined its effects on patients who suffered between four and 14 headaches a month.
"Migraine is a disabling disease for many patients. It disrupts daily living and the ability to function and participate in activities with loved ones," Dr. Sean Harper, executive vice president of Research and Development at Amgen, said in a statement. "The data from our clinical program demonstrate that erenumab has a sustained effect in significantly reducing the number of days people suffer from migraine each month. Based on the benefit-risk profile seen in clinical studies, erenumab is poised to become the first migraine-specific preventive option blocking the calcitonin gene-related peptide, or CGRP, receptor that could help get many patients back to doing the things they love."
Alerts Sign-up